F1D-MC-HGLQ A Randomized, Open-Label Study Comparing the Effects of Olanzapine Pamoate Depot with Oral Olanzapine on Treatment Outcomes in Outpatients with Schizophrenia

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-004157-99

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of the study F1D-MC-HGLQ is to assess the time to all-cause discontinuation in outpatients with schizophrenia who are at risk for relapse, as demonstrated by at least two episodes of clinical worsening in the past 24 months such that the patient was hospitalized or required an increased level of care surrounding the episode. Patients will be treated with either OPD or oral olanzapine for up to 104 weeks of treatment.


Critère d'inclusion

  • Schizophrenia